NCT01383343View on ClinicalTrials.gov

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Recurrent Colon CarcinomaRecurrent Rectal CarcinomaStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal Cancer
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Fluorouracil

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01383343 - Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter